UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
Grant: $325,775 - National Institutes of Health - May. 21, 2009
25% voted satisfied - 75% voted not satisfied - 4 vote(s) cast
Join the conversation: Post a comment about this award
Award Description: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death. Novel therapeutic strategies are urgently needed. With this proposal, we are planning to move toward this goal by gaining a better understanding of the molecular networks that oppose cancer formation. We will characterize the tumor suppressive properties of the promyelocytic tumor suppressor (PML) in NSCLC. In addition, we will test whether PML protein restoration through inhibition of casein kinase 2, an oncogenic protein kinase that contributes to NSCLC tumorigenesis, leads to an antitumor effect in vivo. We will perform these experiments following an integrated strategy that will utilize cellular systems, a faithful mouse model of lung cancer NSCLC and a unique set of novel drugs. This work will provide the framework for the development of a novel strategy for the treatment of this devastating disease.
Project Description: As defined in the Award Description field
Jobs Summary: We have hired a Tech and retained a post-doc (she was paid by other funds that will expire soon). We are also adding one more post-doc that is presently funded by the start-up package. We are in the process of hiring another postdoctoral research fellow with the funding. (Total jobs reported: 2)
Project Status: Less Than 50% Completed
This award's data was last updated on May. 21, 2009. Help expand these official descriptions using the wiki below.
No comments have been added for this project.